Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifapentine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 4/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 3/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.87 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.87 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.87 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.87 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifapentine SCHEMBL29448246 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL29913543 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL29359039 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL20032589 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL41591 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL41590 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL20033121 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL15472877 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL20769769 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL25876809 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170128471-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | SPERO THERAPEUTICS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-20170128471-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | SPERO THERAPEUTICS, INC. | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128471-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | TOP1, TOP2A, TOP2B | MAPT 1923/4885ABCB11 8/4885ABCC4 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.